CYP3A5 and type 2 diabetes mellitus: Additionally, another study reported the association of CYP3A4*18B with the incidence of tacrolimus-induced new-onset diabetes while reporting no association of CYP3A5 variants with new-onset type 2 diabetes in renal transplant recipients [32], but these studies were on study participants with different disease conditions and types of treatment than our study participants that limited direct comparison.